Ferring Pharmaceuticals (https://www.ferring.com/) signed an agreement for the global commercialisation rights to nadofaragene firadenovec/Syn3 (rAd-IFN/Syn3), a novel gene therapy developed by Finnish gene therapy specialists FKD Therapies Oy as a treatment for patients with high-grade non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guérin (BCG) therapy. rAd-IFN/Syn3 is currently undergoing Phase 3 development in the US under the sponsorship of FKD.

LEAVE A REPLY

Please enter your comment!
Please enter your name here